Genenta Science S.p.A. (GNTA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Milan, MI, Italy. The current CEO is Pierluigi Paracchi.
GNTA has IPO date of 2021-12-15, 13 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $12.28M.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
